Notably, RCL1 expression had a significant impact in the prognosis of 8 cancers, including brain lower-grade glioma (LGG), glioblastoma multiforme, kidney renal clear cell carcinoma (KIRC), LIHC, ovarian serous cystadenocarcinoma (OV), uterine corpus endometrial carcinoma (UCEC), uterine carcinosarcoma (UCS), and uveal melanoma (UVM). Here, RCL1 is linked to ovarian serous cystadenocarcinoma.